Clinical Trials in Herlev, Capital Region
1 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled281 locationsNCT06393374
Recruiting
Not Applicable
Benefit of Spectral Information in Patients Suspected for Lung Cancer
Lung Neoplasm Malignant
Copenhagen University Hospital at Herlev1,000 enrolled1 locationNCT06440616